title: IFIT1polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection.
abstract: OBJECTIVE
  To investigate the association between interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) polymorphisms and interferon-α (IFNα) treatment efficiency among Chinese hepatitis B virus (HBV) infection patients.
  
  
  METHODS
  Two hundred and twenty five newly diagnosed chronic hepatitis B (CHB) patients were enrolled in the study. All of these patients received IFNα treatment for a course of 48 wk, and were followed up for 24 wk after the treatment was end. Clinical information about virological response, hepatitis B e antigen (HBeAg) seroconversion rate and combined response at the end of the treatment, as well as the sustained response by the time of following up 24 wk after the treatment, was collected. Four tag-single nucleotide polymorphisms (SNPs) ofIFIT1were selected and assessed for their association with these clinical outcomes.
  
  
  RESULTS
  At the end of the treatment, HBeAg seroconversion was observed in 27.1% patients. Thirty-six point nine percent patients achieved virological response, and 15.6% patients exhibited combined response. Sustained response was obtained in 26.2% patients. The main HBV genotype of the study was genotype B. Patients who infected with HBV genotype B or C showed better treatment efficiency, no matter which clinical outcome was considered. Among the four SNPs assessed, rs303218 (A > G) was found to be significantly associated with the end point virological response when assuming additive model [OR = 0.64 (95%CI: 0.42-0.96),P= 0.032]. Patients who carried rs303218 GG genotype had a rather higher rate of achieving virological response (response rate: 52%, OR = 0.40, 95%CI: 0.18-0.91;P= 0.028) when compared to those had AA genotype (response rate: 27%). The most significant interaction was observed in patients who had relative lower baseline aspartate transaminase. No association between SNPs and HBeAg seroconversion, combined response or sustained response was observed.
  
  
  CONCLUSIONS
  IFIT1involves in the regulation of IFNα treatment for CHB and its polymorphism rs303218 can predict the end point virological response. The finding requires further validation.
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Dong-Ying
authors.initials: DY
authors.lastname: Xie
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Shi-Ming
authors.initials: SM
authors.lastname: Wang
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Jing-Min
authors.initials: JM
authors.lastname: Yang
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Liang-Hui
authors.initials: LH
authors.lastname: Wang
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Chen
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Huai
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Shang
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Mao
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Chun-Liang
authors.initials: CL
authors.lastname: Lei
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Guang-Han
authors.initials: GH
authors.lastname: Luo
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Ji
authors.initials: J
authors.lastname: Qian
authors.affiliation: Dong-Ying Xie, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China.
authors.forename: Da-Ru
authors.initials: DR
authors.lastname: Lu
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002352:Carrier Proteins / Q000235:genetics*; D016009:Chi-Square Distribution; D002681:China; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005838:Genotype; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D000071184:Pharmacogenomic Variants; D020641:Polymorphism, Single Nucleotide; D016601:RNA-Binding Proteins; D012189:Retrospective Studies; D000072230:Sustained Virologic Response; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000998:Antiviral Agents; D015415:Biomarkers; D002352:Carrier Proteins; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; C484290:IFIT1 protein, human; D016898:Interferon-alpha; D016601:RNA-Binding Proteins
keywords: Hepatitis B virus infection; IFIT1; Interferon-α therapy; Polymorphism; Virological response